Skip to main content
Equibles
BRGX logo

BRGX · Bioregenx, Inc. · Metrics

Track BRGX — free

Use BRGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BRGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged May 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern. As reflected in the accompanying financial statements, for the three months ended March 31, 2026, the Company incurred a net loss of $(26,415), generated cash from operations of $26,629 and had a stockholder's deficit of $4,533,316 as of that date. At March 31, 2026, the Company had cash on hand in the amount of $45,806. In addition, notes payable of $522,500 are in default. As a result, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed May 20, 2026
Market Cap
$194,315
Shares
971.58M
Volume · Oct 23 17.6K Avg daily vol (3M) 119.2K

BRGX metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$194,315

Price action

20 metrics
Price change (1W)
-95.0%
Price change (30D)
-96.4%
Price change (3M)
—
Price change (6M)
-97.8%
Price change (YTD)
-98.4%
Price change (1Y)
-98.0%
Trailing year
Price change (5Y)
-99.4%
52-week high
$0.02
52-week low
$0.00
Change from 52-week high
-99.2%
Change from 52-week low
+0.0%
Annualized volatility
428.2%
Annualized volatility (3M)
—
Beta
-0.6
RSI (14D)
37.8
Price vs SMA 50
-96.9%
Price vs SMA 200
-98.3%
Avg volume (3M)
119,200
Relative volume
0.2
Average dollar volume
$596

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
971.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.7×
reciprocal yield 134.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 908.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
7.0
reciprocal yield 14.4%
Earnings yield
-670.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
379.9×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
379.9×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
81.9%
Operating margin
-62.4%
Trailing 12 months
Net margin
-73.8%
Gross profit (TTM)
$1.45M
Operating profit (TTM)
−$1.10M
Net income (TTM)
−$1.30M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
$0.00
EBITDA per diluted share (TTM)
$0.00
Net income per diluted share (TTM)
$0.00
Operating cash flow per diluted share (TTM)
$0.00
Free cash flow per diluted share (TTM)
$0.00
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-17.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.77M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
+253.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-386.6%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.03M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-3.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$1.12M
Latest balance sheet
Cash & equivalents
$45,806
Total assets
$337,070
Total debt
$1.19M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$27,906
Capital expenditures (TTM)
$9,057
R&D (TTM)
$31,750
SG&A (TTM)
$1.81M
Stock compensation (TTM)
$6,782
R&D / revenue
—
Stock compensation / revenue
0.4%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 7.8 days to cover
Days to cover
7.8d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1593184 Visit website